Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Clinical trial NCT00321711 · COMPLETED

Trial details

NCT number: NCT00321711
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

MDS Myelodysplastic Syndromes Thrombocytopenia

Start date: 2006-10-01
Primary completion: 2009-10-19
Enrollment: 69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.